Illumina, Inc.

03.09.2025 - 15:16:17

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

with UK Biobank and a consortium of biopharma collaborators to analyze 50,000 samples with Illumina Protein Prep, the NovaSeq X Plus System, and the DRAGEN Protein Quantification pipeline. The study will generate a new collection of high-quality, NGS-based proteomics data for the research community and pharma partners to advance biological insights.

In June, Illumina announced a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology. The move enhances Illumina's presence in the expanding proteomics market, advances the company's multiomics strategy, and reinforces the value of the NovaSeq X Series as an enabler of the next generation of multiomic applications.

Once the transaction closes, Illumina platforms will continue to support all NGS-based proteomics solutions. Illumina will also continue to support SomaLogic's currently offered array-based proteomics solutions. Until that time, Illumina and SomaLogic remain and will continue to operate as separate entities.

Early-access collaborators will be presenting at upcoming conferences, including the American Society of Human Genetics Annual Meeting in October, visit the event page, and the Human Proteome Organization World Congress in November.

To learn more, visit illumina.com/proteinprep.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, and (iv) our ability to obtain any required regulatory clearances to close our acquisition of SomaLogic, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com